However, even with near complete inhibition of intratumoural 2-HG production, not all IDH mutant glioma models responded to treatment, but only BT142 displayed significant tumour growth inhibition resulting in a measurable survival benefit. The gene discussed is IDH1; the disease is central nervous system cancer.